Page URL: https://www.bionews.org.uk/page_92706

Drug helps to partially reverse cystic fibrosis genetic defect

22 November 2010
Appeared in BioNews 585

American researchers have successfully treated cystic fibrosis patients with a new drug targeting the cause of the disease. Patients carrying a common genetic mutation associated with cystic fibrosis were treated with the drug VX-770. The drug improved their condition by increasing the activity of the chloride ion channel, cystic fibrosis transmembrane conductance regulator (CFTR), which is disrupted in the disease.

'There has never been such a sense of hope and optimism in the cystic fibrosis community. This is the first time there's been a treatment for the basic defect in cystic fibrosis. If we can treat it early, maybe we won't have all the infections that destroy the lungs and eventually takes people's lives away', said Dr Robert Beall, president of the American Cystic Fibrosis Foundation.

Cystic fibrosis is caused by mutations in the CFTR gene, which encodes the CFTR chloride ion channel. Defective CFTR ion channels leads to inadequate transport of chloride ions in the lungs. This causes excess accumulation of thick, sticky, mucus within the lungs, making the body more prone to infections. In the UK over 8,500 children and young adults are affected by cystic fibrosis.

Several different mutations in the CFTR gene can lead to cystic fibrosis. The most common mutation, delta F508, results in severe changes in the structure of the CFTR ion channel. These changes are so severe that the protein is not transported to its site of action at the cells surface. Another common mutation, G551D-CFTR, allows the protein to correctly localise at the cell surface, however it is unable to efficiently transport chloride ions. It is this mutation that was present in the patients selected for the drug trial.

The drug trial assessed the safety of VX-770 and found that its adverse effects were within acceptable limits. The study also examined the functionality of the CFTR ion channel and the lung function of 39 cystic fibrosis patients treated with the drug. Dose-dependent improvements were observed in both CFTR ion channel function and lung function.

'The effects of VX-770 on CFTR-mediated ion transport and lung function suggest that the improvement of CFTR function may be a viable therapeutic approach in cystic fibrosis', write the authors of the study led by Dr Frank Accurso of the University of Colorado.

'Therapies for cystic fibrosis have been limited to alleviating clinical manifestations…This research represents a milestone along the pathway of discovery leading to better preventions, treatments, and cures', writes Dr Michael Welsh, Professor of Medicine at the University of Iowa, who was not involved in the study.

Further studies with larger numbers of patients and for longer durations are required, before VX-770 can be established as a safe and effective drug in the treatment of cystic fibrosis.

This study was published in the New England Journal of Medicine.

SOURCES & REFERENCES
Cystic fibrosis
NHS Choices |  22 March 2010
Drug corrects CF genetic defect
Medpage Today |  17 November 2010
Drug targets faulty process that drives cystic fibrosis
MSN health news |  17 November 2010
Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation
New England Journal of Medicine |  18 November 2010
Targeting the basic defect in cystic fibrosis
New England Journal of Medicine |  18 November 2010
RELATED ARTICLES FROM THE BIONEWS ARCHIVE
30 June 2014 - by Isobel Steer 
A combination of two gene-targeting drugs significantly increases the lung function of cystic fibrosis patients, a clinical trial shows....
19 March 2012 - by Heidi Colleran 
The largest trial for a gene therapy for cystic fibrosis (CF) will begin in the UK this month. Coordinated by the UK Cystic Fibrosis Gene Therapy Consortium (GTC), 130 patients will be recruited and given working copies of the defective gene that leads to their condition...
31 May 2011 - by Dr Kimberley Bryon-Dodd 
Two genetic regions that might explain some differences in disease severity in cystic fibrosis (CF) patients have been identified by US and Canadian researchers. The two regions contain genes that can modify lung function...
21 September 2009 - by Dr Charlotte Maden 
Scientists in the US have found a genetic switch that effects excess mucus production in lung diseases such as asthma and cystic fibrosis (CF), and even the common cold....
26 July 2009 - by Dr Rebecca Robey 
Scientists have used two new techniques to fix defects in lung cells from people with cystic fibrosis, raising hope for new treatments for the disease in the future. The first study, published in the journal Plos Biology, used a gene therapy technique to treat the cells, whilst the second study, published in the American Journal of Respiratory Cell and Molecular Biology, used a drug called miglustat....
6 July 2009 - by Ben Jones 
A Scottish woman is suing Lothian Health Board for medical negligence after a cystic fibrosis (CF) test performed on her while pregnant produced a false negative result. The 41 year old woman from Edinburgh provided a mouthwash sample during her pregnancy in 1994, which tested negative for mutations in her CF gene. However, after her son was born in 1995, it was found that he had inherited the condition from her. Though the test was reported as negative, the claimant alleges that it was actua...
1 March 2009 - by Dr Nadeem Shaikh 
Variations in a gene called IFRD1, linked to activity of white blood cells called neutrophils, may be involved in the severity of symptoms for patients with cystic fibrosis (CF) , according to a new US study published in Nature. CF is a life-limiting inherited disease in which the...
23 February 2009 - by Rosie Beauchamp 
The results of a study carried out at the University of California, Berkeley and the University of Iowa, US have reported significant development in the field of gene therapy. Published this week in the online journal Proceedings of the National Academy of Sciences, the research documents the...
HAVE YOUR SAY
Log in to add a Comment.

By posting a comment you agree to abide by the BioNews terms and conditions


Syndicate this story - click here to enquire about using this story.